A photolabile derivative of phencycliding (PCP), azido phencyclidine (AZ-PCP), was synthesized and used to localize PCP binding sites on the acetylcholine receptor from Torpedo ocellata electric organ. In the dark, the binding of micromolar concentrations of [3H]AZ-PCP to a receptor-enriched membrane preparation fits a single dissociation constant (& = 2.65 PM) and is very similar to the binding of ["HIPCP. The agonist carbamylcholine increases the association rate (and the affinity) of these ligands to the receptor, but it does not alter the total number of available binding sites.
Phencyclidine (PCP) is a synthetic arylcyclohexylamine with multiple actions on animals and humans (Petersen and Stillman, 1978) . Its activity as a general anesthetic (Johnston et al., 1959) and its effects on animal behavior (Petersen and Stillman, 1978) have been known for many years. Interest in PCP has increased in recent years because of frequent abuse of the drug, with harmful consequences. With the development of sensitive binding assays for receptors, studies have indicated that PCP interferes with the binding of several drugs to their muscarinic (Kloog et al., 1977; Gabrielevitz et al., 1980; Vincent et al., 1978; Aronstam et al., 1980) , opiate (Vincent et al., 1978) , and other receptors. The existence ' of specific high affinity binding sites of PCP in rat brain tissue has also been demonstrated (Vincent et al., 1979; Zukin and Zukin, 1979) . It is not known whether the anticholinergic activity of PCP Paster et al., 1974; Kloog et al., 1977; Kalir et al., 1978) contributes to its psychotic activity. The drug is a potent inhibitor of butyrylcholinesterase Kloog et al., 1977) and can block both muscarinic Kloog et al., 1977) and nicotinic (Kloog et al., 1977; Albuquerque et al., 1980) responses in tissues. It is now recognized that PCP can act as a noncompetitive blocker of the nicotinic response to acetylcholine (AcCho). This finding was based on electrophysiological as well as on binding Kloog et al., 1979 Kloog et al., , 1980 data indicating that PCP blocks the cholinergic ionophore. PCP does not inhibit binding of the specific nicotinic neurotoxin a-bungarotoxin (a-Bgt) , and binds to specific binding sites in Torpedo electric organ membrane that are distinct from AcCho binding sites Kloog et al., 1979 Kloog et al., , 1980 Oswald and Changeux, 1981a) . As with other noncompetitive blockers of AcCho (Oswald and Changeux, 1981a; Kloog et al., 1979; Elliott and Raftery, 1979) , the binding of PCP is enhanced by the agonist carbamylcholine Oswald and Changeux, 1981a) . Thus, all of the data suggest that PCP interacts directly with the acetylcholine receptor (AcChoR).
The AcChoR from Torpedo electric organ is a pentamer composed of four different polypeptides with apparent molecular weights of -40,000 (a), -50,000 (p), -60,000 (y), and -65,000 (6) (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . Two CY subunits are present in each pentamer and on them are located the binding sites for AcCho and snake toxins (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . If PCP does indeed act directly on the AcChoR, it could be expected to interact with at least one of the receptor subunits. In order to localize the site on the AcChoR to which PCP would bind, we have synthesized a photolabile derivative of PCP, azido phencyclidine (AZ-PCP), and used it to label receptors on membranes purified from electric organ of Torpedo ocellata. Azido derivatives of drugs have the advantage that they can be used under two sets of conditions: those in which they bind reversibly and those in which they irreversibly inactivate their binding sites.
We report here on the specific labeling of LU and p subunits of the AcChoR from T. ocellata by [3H]AZ-PCP. The simplest explanation accommodating both the binding and the labeling data obtained is that the binding site for PCP is located close to the physical connection between the (Y and p subunits, enabling the ligand to attach simultaneously to both.
Materials and Methods
Phencyclidine and 3-aminophencyclidine (l-(1-(3-aminophenyl)-cyclohexyl)piperidine) were prepared as described (Kalir et al., 1978) . 3-Azido phencyclidine (l-(1-(3-azidophenyl)-cyclohexyl)piperidine) was prepared from 3-aminophencyclidine by dissolving it in 1 M hydrochloric acid, treating it with KN02, and then adding NaN3 as described previously (Amitai et al., 1982) . Compounds were characterized by C, H, N analysis and infrared spectroscopy and were tested for purity (>98%) by two thin layer chromatography systems (Kalir et al., 1978) . The melting point of the AZ-PCP (free base) was 51 to 52°C.
[3H]PCP (22.5 Ci/mmol) was prepared by catalytic tritium exchange and was tested for purity (>98%) as described elsewhere (Kalir et al., 1978) , using a synthetic technique analogous to that described by Kalir et al. (1975) .
[3H]AZ-PCP (27.1 Ci/mmol) was prepared by diazotation of tritiated aminophencyclidine followed by reaction with sodium azide. Purity was >99%.
Decamethonium, hexamethonium, tetracaine, carbamylcholine, d-tubocurarine, CY-Bgt, and quinacrine were obtained from Sigma.
Tissue preparation. Membranes rich in acetylcholine receptor were prepared from 150 gm of freshly dissected electric organ of live T. ocellata (caught off the Mediterranean coast of Tel-Aviv), as described by Saitoh et al. (1980) . The electric organs were homogenized in 50 mM Tris-HCl buffer, pH 7.4, in the presence of 0.1 mM phenylmethylsulfonyl fluoride, 3 mM EDTA, 1 mM EGTA, 5 units/ml of aprotinine and 5 pg/ml of pepstatin A. The pellet (p3j was resuspended in 36% sucrose (w/ w), sonicated, and then layered on top of 41% sucrose and centrifuged at 43,000 rpm in a Beckman 45 Ti rotor for 3 hr. The membrane fragments located at the interface were collected and further purified by alkaline treatment (Neubig et al., 1979) . The pH was adjusted to 11 using 1 M NaOH, and the mixture was incubated for 60 min at room temperature and then centrifuged at 4°C for 30 min at 194,000 X g. The pellet was resuspended in the homogenization buffer. The membranes were either used immediately or stored at -70°C until use. Specific a-Bgt binding sites were determined by means of the DEAE filter disk assay (Schmidt and Raftery, 1973) , using lz51-labeled a-Bgt. The purified AcChoR-rich membrane fragments had a specific activity of 1.6 to 2.0 nmol/ mg.
Binding assays. Binding of [3H]PCP and 13H]AZ-PCP was assayed by both the centrifugation and the filtration methods. The latter ligand was assayed in the dark. In the centrifugation method, aliquots (50 ~1) of membrane preparation containing 40 to 60 pg of protein were pipetted into plastic microfuge tubes containing 100 ~1 of buffered [3H]PCP or [3H]AZ-PCP and either 50 ~1 of Torpedo physiological buffer (250 mM NaCl, 5 mM KCl, 2 mM MgCl*, 2 mM CaC12, 50 mM sodium phosphate, pH 7.0) or 50 ~1 of buffer containing ligand. Following incubation at 25°C for 30 min to reach equilibrium, the tubes were centrifuged for 4 min (Eppendorf microfuge, model 5415). The supernatant was sampled for determination of free ligand and was discarded. The pellets were washed rapidly three times with 1 ml of ice-cold buffer. The tip of the tube was cut and its contents collected in scintillation vials containing 4 ml of scintillation liquid (Hydro-Luma, Lumac Systems), stirred with a vortex, and kept at room temperature for 24 hr. Counting was carried out in a Packard Prias-PL, with a counting efficiency of 40%.
When binding was assayed by the filtration method the reaction was terminated by filtration on Whatman GF/C glass filters which were washed twice with 3 ml of buffer. Adsorbance of the labeled drugs to the filters in the absence of membranes was low (10% of total binding). It was measured both in the absence and in the presence of 5 x lop4 M unlabeled PCP and was subtracted from the counts of corresponding samples measured in the presence of membranes.
All We also examined the effect of varying some of the photolysis conditions in the case of [3H]AZ-PCP membrane complexes, such as the time of photolysis and the distance of the membranes from the photolysis source. The highest specific irreversible binding of [3H]AZ-PCP was observed under the conditions described above.
Gel electrophoresis. The SDS polyacrylamide gel electrophoresis procedure was carried out as described by Laemmli (1970) . Membrane samples were dissolved 1:l (v/v) in 2 X sample buffer (52.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol) and applied to polyacrylamide slab gels (8.0%). Proteins were electrophoresed at 15 to 20 mA/slab for 3 hr, then stained with 0.2% Coomassie brilliant blue in 50% methanol and 7% acetic acid and destained in 7.5% acetic acid. Gels were sliced into l-mm sections with a gel slicer. Each slice was digested in 5 ml of 6% Protosol (New England Nuclear) in Hydro Luma in a closed scintillation vial. Radioactivity was determined after 24 hr by liquid scintillation spectrometry.
Other gels were prepared for fluorography as described (Bonner and Laskey, 1974) , and exposed to an Agfa x-ray film (Curix RP-2) which was developed 30 days later (Kodak x-ray developer and fixer).
Results

Common binding sites for rH]PCP
and rH]AZ-PCP. Previous studies have shown that [3H]PCP (Kloog et al., 1979,198O; Oswald and Changeux, 1981a) and its amino derivative and did not change when measured in the presence of other ligands known to interact with PCP binding sites (not shown).
As shown in Figure Haring et al. Vol. 4, No. 3, Mar. 1984 and ["H]AZ-PCP (defined as the total minus nonspecific binding sites (AcCho binding sites) Oswald and Changeux, 1981a ) and its competitive displacement by aminated local anesthetics and other noncompetitive blockers of AcCho Kloog et al., 1980; Oswald and Changeux, 1981a 1, a and b) . Quinacrine and the local anesthetic tetracaine inhibited their binding (Fig. 2) . In addition, PCP inhibited
[3H]AZ-PCP binding to the receptor. It should be noted that, although carbamylcholine increased the affinity of the labeled ligands toward their binding sites, it did not increase their binding capacity (Fig. 1 , Table I ). The increased affinity is at least partly due to the increased rate of association of [3H]PCP to the receptor-enriched membrane, which in turn is dependent on the concentration of the agonist Photoaffinity labeling of the AcChoR with AZ-PCP. The dark-stable property of AZ-PCP enables the characterization of its reversible binding properties. It also allows experimental separation of the binding reaction from the photoinactivation process. Conditions for the latter were selected empirically and are described under "Materials and Methods." The amount of labeled drug which remained attached to the membranes after photolysis was compared with the amount of reversible bound ["H]AZ-PCP.
The dose-dependent enhancement of [3H]PCP binding induced by carbamylcholine is shown in Figure 3 . The effect is observed already at 0.1 ELM carbamylcholine, reaches maximal level at -1 pM, and does not fade even at 10e3 M. When 1 PM c.u-Bgt is present in the incubation medium, the carbamylcholine-induced enhancement of [3H]PCP binding is blocked, but there is no effect on the basal level of PCP binding (Fig. 3~) . Moreover, the presence of the toxin did not increase the inhibition of [3H]PCP binding by PCP. These data confirm previous findings suggesting that PCP does not bind to the a-Bgt Figure 4 shows that 20 to 30% of the specifically bound drug remained attached to the membrane after UV irradiation and dilution. At higher concentrations of [3H] AZ-PCP, more of the drug remained attached. Similar results were obtained when the membranes were precipitated and washed (Fig. 4) . More than 95% of the specifically bound [3H]AZ-PCP disappeared when the membranes were not irradiated and diluted, indicating that the irreversible attachment of the drug to the membranes was indeed a result of the photolysis. Attempts to increase the yields of [3H]AZ-PCP photoinactivated binding sites by varying the time of exposure to UV light and by using a short wave UV lamp (245 nm) failed. Nevertheless, the high specific activity of the azido derivative and enrichment of the membranes in specific binding sites enabled us to further characterize those binding sites to which the drug had been covalently attached. Identification of AZ-PCP labeled receptor subunits. To identify the polypeptides in the AcChoR-enriched membranes to which [3H]AZ-PCP is attached, SDS polyacrylamide gel electrophoresis was used. Membranes were subjected to electrophoresis after photoaffinity labeling under the standard conditions. The gels were stained, destained, and either cut for counting or used for fluorography.
A typical fluorogram is shown in Figure 5 . Several bands are observed, corresponding to polypeptides with apparent molecular weight of 92,000, 80,000, 65,000, 55,000, 50,000, and 40,000. The last four correspond to the well described AcChoR subunits (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . In the presence of lop3 M PCP (Fig. 5A ) or 10e3 M tetracaine (Fig. 5B) , the labeling intensity of all of the polypeptides observed in the gel was strongly reduced.
The 40,000-dalton subunit was the most intense band observed when the membranes were labeled in the absence of carbamylcholine (Fig. 5, A and B) . On the other hand, in the presence of 1O-5 M (Fig. 5A ) or lop4 M (Fig.  5B) carbamylcholine, the intensity of the 50,000-dalton subunit was enhanced, while no apparent effect on the other polypeptides was observed. Similar enhancement was induced by d-tubocurarine (lop6 M) (Fig. 5B) . The data presented in Figure 6 demonstrate that the enhancement by carbamylcholine of the labeling of the 50,000-dalton subunit can be blocked by 1 pM a-Bgt. Like the fluorograms (Fig. 5) , direct counting of the gels (Fig. 6) showed that the 40,000-dalton subunit is labeled both in or diluted 500-fold and filtered after 60 min (0, -U.V., "dilution").
The rest of the mixture was irradiated under the standard conditions as described under "Materials and Methods." After photolysis, lo-~1 samples were diluted 500-fold in Tris buffer and filtered 60 min later (A, +U.V., "dilution").
The rest of the membranes were centrifuged, and the pellets were resuspended and washed four times with 3 ml of 50 mM Tris buffer, pH 7.4, collected and counted (A, +U.V., "Washed" pellets). Each data point represents the specifically bound ligand (i.e., total minus nonspecific binding). the absence and in the presence of carbamylcholine and that the labeling of the 50,000-dalton subunit is enhanced by this cholinergic agonist.
Discussion
The cholinergic effects of PCP and its derivatives have been extensively described Paster et al., 1974; Kloog et al., 1977; Kalir et al., 1978; Petersen and Stillman, 1978) . However, it was recognized only recently that these drugs may interact directly with the cholinergic ionophore (Kloog et al., 1979 Albuquerque et al., 1980; Oswald and Changeux, 1981a) . Electrophysiological as well as binding studies Kloog et al., 1980; Oswald and Changeux, 1981a) suggest that PCP acts as a noncompetitive blocker of AcCho. Thus, the drug appears to fall into the pharmacological category of local anesthetics (Webber and Changeux, 1974; Karlin, 1980) and related drugs (Elliott and Raftery, 1979; Albuquerque et al., 1980) rather than that of the cholinergic agonists and their competitive rarine + 1 pM cw-Bgt (0). When ol-Bgt was used, the membranes were pre-incubated with the toxin for 30 min at room temperature. Decamethonium, hexamethonium, and d-tubocurarine were added 5 min prior to the addition of ["HIPCP. antagonists. The binding sites for the latter are located on the two QOOO-dalton CY subunits of the nicotinic acetylcholine receptor (Karlin, 1980; Conti-Tronconi and Raftery, 1982) .
To localize the sites on the AcChoR onto which PCP would bind, we synthesized an azido derivative of PCP and used it as a photoaffinity probe. Azido derivatives of drugs have the advantage that they can be examined under two sets of conditions: those in which they bind reversibly and those in which they irreversibly inactivate their binding sites. Their disadvantage is that incorporation of the azido group may interfere with the drug's specificity. Therefore, when using an azido derivative, it is important to start by examining its specificity (Bayley and Knowles, 1977; Zisapel and Sokolovsky, 1977) .
In our detailed analysis of the binding of AZ-PCP, we demonstrated that its binding properties are almost indistinguishable from those of the parent molecule, PCP. That is, both drugs bind with high affinity to AcChoRenriched membranes from Torpedo electric organ, the number of specific binding sites is identical in both, their binding is inhibited by noncompetitive blockers of AcCho, they competitively inhibit each other's binding, and their binding is similarly enhanced by cholinergic drugs like carbamylcholine and d-tubocurarine. These similarities confirm the suitability of AZ-PCP as a photoaffinity probe for PCP binding sites in Torpedo electric organ membranes. In the absence of carbamylcholine, several polypeptides in the AcChoR-enriched membranes are labeled by AZ-PCP. Among them are the 65,000-, 55,000-, 50,000-, and 40,000-dalton polypeptides, which correspond, respectively, to the receptor subunits 6, y, j3, and (Y (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . Two other labeled bands correspond to polypeptides with apparent molecular weights of 92,000 and 81,000. The amount of labeling of these two polypeptides varied between experiments and was not affected significantly by cholinergic drugs or local anesthetics. The nature of their labeling is still unknown. The presence of these two polypeptides in receptor-enriched membranes from Torpedo electric organs, however, has been previously established (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . Unlike the labeling of these two polypeptides, labeling of the four Figure 6. SDS polyacrylamide gel electrophoresis of ["H]AZ-PCP photolabeled receptor-enriched membranes. Membranes were treated as described for Figure 5 , except that the gels were sliced and counted as described under "Materials and Methods." Incubations were under the following conditions: a, No carbamylcholine; b, + 100 pM carbamylcholine (0) or + 100 pM carbamylcholine + lo-" M tetracaine (0); c, + 100 pM carbamylcholine + 10 pM cu-Bgt.
polypeptides which correspond to the AcChoR was consistently observed in all of our experiments.
By far the most heavily labeled band was that corresponding to the (Y subunit, which is known to carry the AcCho binding sites (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . Labeling of this subunit was strongly inhibited by both PCP and tetracaine. The snake venom a-Bgt, however, did not block labeling of the (Y subunit when used at a concentration (1 pM) at which it completely blocks AcCho binding sites (Eldefrawi et al., 1982) . Therefore, the binding of AZ-PCP to the a! subunit must occur on sites other than the AcCho binding sites. Indeed, addition of carbamylcholine (10 pM) did not affect labeling of the (Y subunit; however, it caused a strongly enhanced labeling of the 50,000-dalton polypeptide (the 0 subunit). Labeling of the /3 subunit was inhibited by PCP and tetracaine, and the effect of carbamylcholine was blocked by ol-Bgt. Therefore, we conclude that the p subunit carries specific binding sites for PCP. Moreover, it is evident that the occupation of AcCho binding sites by carbamylcholine leads to enhanced binding of AZ-PCP to the 0 subunit, probably via the known conformational changes induced by the agonist (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . Therefore, the observed increase in affinity of PCP to its binding sites is at least partly due to the stronger attachment of the ligand to the p subunit in the presence of carbamylcholine than in its absence. In the absence of cholinergic agonist, the membrane-bound receptor is present mostly in its resting state, while in its presence it is in its desensitized form Sugiyama et al., 1976) . Thus, AZ-PCP binds preferentially to the (Y subunit when the receptor is in its resting state and to both the (Y and p subunits when the receptor is in the desensitized state.
We consistently observed an enhanced labeling of the /I subunit in the presence of carbamylcholine. In earlier experiments, Oswald et al. (1980) demonstrated that labeling of a 50,000-dalton polypeptide by azido trimethisoquin was enhanced by carbamylcholine. They later showed that this labeled band was a proteolytic product of the 6 subunit (Saitoh et al., 1980) . In other studies, Oswald and Changeux (1981b) demonstrated that labeling of the 6 subunit also occurs in the presence of other noncompetitive blockers of AcCho, such as perhydrohistionicotoxin (Hi2-HTX) and PCP. Although we did observe labeling of the 6 subunit with AZ-PCP, we did not observe an increase in its labeling in the presence of carbamylcholine. This discrepancy cannot be explained by assuming the presence of proteolytic enzymes. We investigated the effect of using inhibitors of the four major classes of proteolytic enzymes, during both the membrane purification and the reactions. The latter were performed with and without enzyme inhibitors, and the results were the same in each case, both in binding experiments and on the gels. Purification of membranes in the absence of protease inhibitors resulted in the appearance of additional Coomassie blue-stained bands labeled by AZ-PCP at molecular weights lower than 40,000 (not shown). However, even under these conditions, labeling of the /3 subunit was enhanced in the presence of carbamylcholine. If a highly active protease were present in our preparations, we should have seen at least a residual enhancement effect on the 6 subunit when protease inhibitors were used, if this were the original target for AZ-PCP. Therefore, we suggest that the discrepancy between our work and that of Changeux may stem from species differences (T. ocellata was used here, whereas the other study used Torpedo marmorata (Oswald and Changeux, 1981a, b) .) Recent studies have indeed indicated that species differences determine the AZ-PCP labeling pattern in desensitized nicotinic acetylcholine receptors (Haring et al., 1983) . Carbamylcholine enhanced the labeling of the fl subunit in T. ocellata, the 6 subunit in T. marmorata, and the 01 subunit in Torpedo californica. Furthermore, Kaldany and Karlin (1983) have recently demonstrated that carbamylcholine enhances the labeling of (Y and p subunits in T. californica by quinacrine mustard.
At the micromolar concentration range, binding of [3H]PCP and ["HIAZ-PCP is saturable both in the presence and in the absence of carbamylcholine. We found no evidence supporting the existence of two or more binding sites for either labeled ligand. The labeling experiments clearly demonstrate, however, that at least the 01 and p receptor subunits were labeled. One possible explanation for this apparent discrepancy is that the binding sites on the 01 and p subunits are independent of each other, and in the absence of carbamylcholine the affinity of PCP toward both is similar and thus undetectable in our binding measurements. If PCP binds independently to LY and fl subunits, ,an increase in maximal binding capacity should have been observed in the presence of carbamylcholine. That is, we should have seen binding to two populations of sites with low and high affinity, reflecting binding to CY and p subunits, respectively. We did not detect either an increase in the binding capacity or heterogeneity of binding. Therefore, it is unlikely that PCP at the micromolar range binds independently to a! and /3 subunits.
Another plausible explanation is that the PCP binding site is located in the vicinity of the physical connection between the two subunits, and that consequently the PCP molecule is attached simultaneously both to ~1 and /3 subunits. In proposing such a hypothesis, we assume that one moiety of the PCP molecule is attached to the a and the other to the p subunit. Addition of carbamylcholine in this case should increase only the attachment between the p subunit and its PCP moieties; that is, we should observe no increase either in the number of PCP binding sites or in heterogeneity, but only an increase in affinity. This was indeed the experimental finding, but we should keep in mind that the azido moiety (through which the drug is covalently attached to the receptor subunits) is located on the phenyl ring. If our hypothesis is correct, this would suggest that there are nonidentical overlapping binding sites for PCP on the AcChoR subunits. The receptor subunits (at least ac and 0) would then require specific recognition sites for both the phenyl moiety and the other (cationic nitrogen) moieties of PCP. The high degree of amino acid sequence homology between the receptor subunits (Conti-Tronconi et al., 1982a) and the asymmetric structure of the pentameric AcChoR (Karlin, 1980) are compatible with our hypothesis.
In previous reports Oswald and Changeux demonstrated that radiolabeled azido trimethisoquin (1981a), Hip-HTX, PCP, and trimethisoquin (1981b) label all of the AcChoR subunits. Like our results with AZ-PCP, in the absence of cholinergic ligand the 01 subunit was always the most heavily labeled band. Labeling of the (Y subunit with trimethisoquin was inhibited by carbamylcholine and erabutoxin b (Oswald and Changeux, 1981b) , but labeling of the a subunit with PCP was not affected by these ligands. These results are in agreement with our own finding that at the micromolar concentration range the attachment of PCP to the LY subunit is not via AcCho binding sites. However, in view of the heavy labeling of the Q! subunit by all noncompetitive blockers of AcCho tested so far, we suggest that the 01 subunit must be considered as a target for these drugs. Accordingly, local anesthetics can also bind to PCP sites on the cy subunit. This suggestion is supported by binding data indicating that all of the binding of any of the ligands can be displaced by the others. That is, PCP binding can be displaced by H12-HTX and local anesthetics Kloog et al., 1980 ) (see Fig. 4 ), and Hi2-HTX binding or meproadifen binding can be displaced by local anesthetics or PCP (Elliott and Raftery, 1979; Krodel et al., 1979; Albuquerque et al., 1980) . Moreover, the number of the high affinity sites for meproadifen , PCP , and Hlz-HTX in receptor-enriched membranes is similar (the ratio of noncompetitive drug sites to c.u-Bgt sites is between 0.25 and 0.35).
We have shown that cholinergic ligands, such as cyBgt and carbamylcholine, in concentrations at which they completely block AcCho binding sites, do not interfere with the high affinity PCP or AZ-PCP binding. However, we know that other cholinergic drugs, such as d-tubocurarine, at concentrations well above those needed to block AcCho sites, do block the high affinity PCP (Fig. 3) or Hi*-HTX binding (Shaker et al., 1982) . Eldefrawi et al. (1982) also demonstrated that nicotine and decamethonium can interact with Hi*-HTX binding sites on the AcChoR when the AcCho sites are blocked by cu-Bgt. Therefore, it seems that several cholinergic ligands can also bind to PCP binding sites but with a lower affinity than to the AcCho sites. It should be noted that from other experiments we know that the cy subunit can bind local anesthetics at the AcCho site. Meproadifen , trimethisoquin (Oswald and Changeux, 1981a, b) , and quinacrine (Tsai et al., 1979) are the best examples. It is interesting to note that Conti- Tronconi et al. (198213) reported recently on a low affinity binding site for AcCho that is distinct from the high affinity AcCho binding site. The localization of the low affinity site is still unknown. Data presented here and by others indicating low affinity binding of cholinergic drugs to PCP or HI,-HTX binding sites (Eldefrawi et al., 1982) open the possibility that these sites are the low affinity AcCho binding sites.
To summarize, the binding characteristics of noncompetitive blockers of AcCho as well as our photoaffinity labeling experiments suggest that at least two binding sites on the AcChoR are recognized by both the noncompetitive blockers and the cholinergic drugs. One of these is the well known AcCho site located on the LY subunit. This site preferentially binds cholinergic drugs such as AcCho, d-tubocurarine, carbamylcholine, and cu-Bgt (Karlin, 1980; Conti-Tronconi and Raftery, 1982) . It can also bind local anesthetics, such as meproadifen , trimethisoquin Changeux, Vol. 4, No. 3, Mar. 1984 1981a) , and possibly PCP as well, but with lower affinity. The second site on the AcChoR preferentially binds PCP and probably local anesthetics as well. It can also bind cholinergic drugs, but with lower affinity. According to our hypothesis, the second site is localized between the (Y and fl subunits of the AcChoR from T. ocellata. This model is similar to that described for the binding of phosphoglycerate to the two @ subunits of hemoglobin (Baldwin and Chothia, 1979) . Since local anesthetics and related drugs exhibit many common features when acting on the AcChoR, we believe that such a model explains the interaction of all of them. However, differences between the actions of various local anesthetics and other channel blockers have also been reported (Eldefrawi et al., 1982) . Thus, additional quantitative data are needed on the labeling of receptor subunits with PCP and local anesthetics.
It would now be of great interest to localize the polypeptides to which PCP binds in mammalian brain membranes. These membranes have been shown to possess high affinity binding sites for PCP (Vincent et al., 1979; Zukin and Zukin, 1979) . If AZ-PCP binds like PCP to the high affinity PCP binding sites in brain membranes, it will be able to serve as a potent photoaffinity probe for these sites.
